India, Hyderabad; 06th September, 2021: Hetero, a globally renowned vertically integrated pharmaceutical organization announced today that the Drug Controller General of India (DCGI) has issued for restricted use, Emergency Use Authorization (EUA) for the generic version of Tocilizumab in India. This authorization will enable the medical practitioners to use the generic drug Tocilizumab for the treatment of Covid-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non- invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Dr. B. Partha Saradhi Reddy, Chairman, Hetero Group said: ?We are pleased with the approval of Hetero?s Tociluzumab (Tocira) in India. This demonstrates our technical capabilities and commitment to bringing important therapeutics relevant to COVID care. This approval is extremely crucial for supply security in India considering a global shortage of Tociluzumab. We will be working closely with the Government to ensure equitable distribution.? Hetero?s TOCIRA (Tocilizumab) will be marketed by its associate company ?Hetero Healthcare? in India with the support of its strong distribution network across the country. Hetero?s biologics arm ?Hetero Biopharma? will be manufacturing the drug at its dedicated biologics facility, based at Jadcherla in Hyderabad, India. Hetero?s Tocilizumab 400mg/20ml is the biosimilar version of Roche?s Actemra/RoActemra ?, and will be available from September end. About Hetero Hetero is a globally renowned vertically integrated pharmaceutical organization engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero?s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world. Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide. Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment. For more information on Hetero, please visit www.heteroworld.com. For further details, please contact: Fortuna PR Vishal Kumar Mob: 98855 85802 Email: vishal@fortunapr.com Priya K Mob: 95354 25418 Email: priya@fortunapr.com